Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [Gastrointestinal Cancer]

Conclusion
The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Andre, de Gramont, Vernerey, Chibaudel, Bonnetain, Tijeras-Raballand, Scriva, Hickish, Tabernero, Van Laethem, Banzi, Maartense, Shmueli, Carlsson, Scheithauer, Papamichael, Moehler, Landolfi, Demetter, Colote, Tournigand, Louvet, Duval, Flejou, de Gramon Tags: Chemotherapy, Translational Oncology Gastrointestinal Cancer Source Type: research